hrp0092p1-102 | Pituitary, Neuroendocrinology and Puberty | ESPE2019

Clinical Presentation, Management, and the Outcomes of Pituitary Adenomas in Children

Sethi Aashish , Didi Mohammed , Dharmraj Poonam , Ramakrishnan Renuka , Senniappan Senthil , Das Urmi , Avula Shivaram , Sinha Ajay , Mallucci Conor , Daousi Christina , Gilkes Catherine , Thorp Nicola , Blair Joanne

Introduction: Pituitary adenoma (PA) in childhood is a rare disease, accounting for 3 % of all intracranial paediatric neoplasm, and between 3 to 6% of all PA. There are only few large studies describing paediatric pituitary adenoma and even fewer studies with long-term outcome.Methods: In this retrospective study, clinical, biochemical and radiological parameters and outcome of paediatric patients (<16 years...

hrp0082wg5.6 | Paediatric and adolescent gynaecology | ESPE2014

Contraception in Adolescence: Current Options

Gordon Catherine

Adolescent girls may present to their pediatric or reproductive endocrinologist seeking advice regarding contraception. In 2014, there are many methods available, and the risks and benefits of each must be weighed in determining which method is most appropriate for a given patient. This lecture will provide an overview of contraceptive methods, with a focus on oral contraceptive pills, transdermal patches, and the vaginal ring. Methods will be reviewed with a focus on thrombot...

hrp0089p3-p131 | Fat, Metabolism and Obesity P3 | ESPE2018

Development of Severe Obesity in a Children with a Brainstem Tumor

Pihoker Catherine , Roth Christian

The homeostatic control of energy balance is tightly regulated. Appetite and energy expenditure regulation involves neurons in the hypothalamus as well as other brain regions, including the limbic system, amygdala and the brainstem. Hypothalamic obesity is a well-recognized consequence of lesions such as craniopharyngiomas and other tumors in the hypothalamic region. Less known is obesity related to tumors in other brain regions. The child presented at 14 years of age with fai...

hrp0094p2-6 | Adrenals and HPA Axis | ESPE2021

Single centre experience of Hydrocortisone Granules (Alkindi) in children under 6 years of age with Adrenal Insufficiency

Snow Claire , Owen Catherine ,

Introduction: Children with Adrenal insufficiency (AI) are usually managed with glucocorticoid replacement as hydrocortisone. Treatment options in younger patients include administering an aliquot of 10mg hydrocortisone tablets dissolved in water. However, this is time consuming and may be inaccurate. We describe our experience of using Alkindi (www.diurnal.co.uk), the first hydrocortisone preparation licensed for children with AI.<stron...

hrp0089p3-p121 | Diabetes &amp; Insulin P3 | ESPE2018

Pediatric Stroke as the Presenting Symptom of New Onset Diabetes without DKA

Bharill Sonum , Constantacos Cathrine

Introduction: Neurologic symptoms, such as cerebral edema, stroke, and extrapontine myelinolysis, are rare in pediatric patients with type 1 diabetes mellitus (T1DM) in the absence of severe diabetic ketoacidosis (DKA) or chronically poor glycemic control. Ischemic or hemorrhagic stroke may account for 10% of intracerebral complications of DKA. DKA increases the risk for neurovascular compromise by several proposed mechanisms, including dehydration, hyperosmolarity, tissue hyp...

hrp0086p2-p947 | Thyroid P2 | ESPE2016

Delayed Diagnosis of a TSH-Adenoma due to Coexisting Autoimmune Thyroid Disease

Crudo David , Constantacos Catherine , Walsh Elizabeth

Background: TSH-secreting pituitary adenomas are rare, accounting for less than 2% of all pituitary adenomas. Their diagnosis may be difficult when a coexistence of other diseases masks the typical clinical and biochemical manifestations of TSH-hypersecretion.Objective: To report a case of a TSH-adenoma without signs/symptoms of hyperthyroidism due to underlying autoimmune thyroid disease.Results: Patient is a 17 year old male who ...

hrp0082p3-d3-848 | Growth (2) | ESPE2014

Severe Short Stature with Features of Achondroplasia, Later Diagnosed as Panhypopituitarism: a Case Report

Matei Cristina , Karam Maria , Peters Catherine

Background: Severe short stature is considered when height falls below −4 SDS. When infants with extreme short stature are evaluated, often multidisciplinary input is required, before a formal diagnosis is met.Objective and hypotheses: We want to learn from delayed diagnosis of child with panhypopituitarism and review subsequent difficulties in starting GH treatment.Method: Retrospective review of notes, investigations and pa...

hrp0084p3-1207 | Thyroid | ESPE2015

Neonatal Hyperthyrotropinaemia – Watchful Waiting vs Treatment: Experiences from a Tertiary Centre

Ponmani Caroline , Peters Catherine , Langham Shirley

Background: Neonatal hyperthyrotropinaemia (HT) is defined by elevated TSH and normal fT4. HT is an increasingly common diagnosis and may be transient or permanent. There is a often a diagnostic dilemma whether to treat to prevent subclincal hypothyroidism or to wait thereby avoiding the risks of iatrogenic hyperthyroidism.Objective and hypotheses: To examine a large population of infants referred to a tertiary centre over one year and determi...

hrp0089p1-p190 | Multisystem Endocrine Disorders P1 | ESPE2018

Overview of Leading Causes of Death among French Patients with Prader-Willi Syndrome, 2004–2014

Liz Pacoricona Alfaro Dibia , Lemoine Perrine , Molinas Catherine , Diene Gwenaelle , Arnaud Catherine , Tauber Maithe

Introduction: Prader-Willi Syndrome (PWS) is a complex neurodevelopmental genetic disease comprising multiples cognitive, behavioural and endocrine abnormalities. This rare syndrome is one of the most common known reasons of syndromic obesity, a major cause of morbimortality among this population. In the last 20 years, substantial improvements have been made regarding the diagnosis, treatment and management of patients with PWS. Along those progresses, national policies were d...

hrp0095rfc5.1 | Adrenals and HPA Axis | ESPE2022

Single centre use of Hydrocortisone granules (Alkindi) in children with Adrenal Insufficiency: the patient experience.

O'Sullivan Jacqueline , Snow Claire , Wood Claire , Owen Catherine

Standard management of Adrenal Insufficiency (AI) in children is with hydrocortisone (HC). Under or over-treating impacts on growth and quality of life. Until recently, treatment involved dissolving 10mg HC tablets in water; this is time consuming and may give inaccurate doses. We have offered HC granules (Alkindi) to all new patients ≤6-years since January 2019 and 22 patients who were currently dissolving HC tablets. We have reviewed our patients’ experience with Al...